Patents Assigned to Wyeth
  • COMPOSITIONS AND METHODS OF USE OF ORF1358 FROM BETA-HEMOLYTIC STREPTOCOCCAL STRAINS
    Publication number: 20090318359
    Abstract: The present invention relates to polynucleotides encoding Streptococcus group C and G polypeptides and their use in immunogenic compositions. The invention also relates to immunogenic compositions comprising polypeptides encoded by those polynucleotides. In addition, the invention relates to methods of inducing an immune response in mammals against beta hemolytic Streptococcus or beta hemolytic Streptococcus infection using immunogenic compositions of the Streptococcus group C and G polypeptides and polynucleotides.
    Type: Application
    Filed: June 19, 2009
    Publication date: December 24, 2009
    Applicant: Wyeth
    Inventors: Ellen Murphy, Emily Mara Braunstein, Dorys Garcia-Hand, Annaliesa Sybil Anderson, Ingrid Lea Dodge, Eduardo Arturo Rojas
  • METHODS FOR ENHANCED PRODUCTION OF BONE MORPHOGENETIC PROTEINS
    Publication number: 20090317867
    Abstract: Methods and processes for improved recombinant protein production are provided. The methods are useful for production of growth factors, particularly those of the TGF-? superfamily, including bone morphogenetic proteins (BMPs), such as BMP-2. Suitable host cells are cultured in media where iron is present at a concentration of at least 2.25 ?M and if pyridoxal is present, it makes up less than 55% of the molar concentration of vitamin B6 in the media.
    Type: Application
    Filed: April 16, 2009
    Publication date: December 24, 2009
    Applicant: Wyeth, Madison, New Jersey
    Inventors: Yen-Tung Luan, Wenge Wang, Gregg Nyberg, Jose Manuel Gomes, Denis Drapeau, Terry Cardoza
  • Anti A? antibody formulation
    Patent number: 7635473
    Abstract: The present invention provides formulations for maintaining the stability of A? binding polypeptides, for example, A? antibodies. Exemplary formulations include a tonicity agent such as mannitol and a buffering agent or amino acid such as histidine. Other exemplary formulations include an antioxidant in a sufficient amount as to inhibit by-product formation, for example, the formation of high molecular weight polypeptide aggregates, low molecular weight polypeptide degradation fragments, and mixtures thereof. The formulations of the invention optionally comprise a tonicity agent, such as mannitol, and a buffering agent or amino acid such as histidine. The formulations are suitable for several different routes of administration.
    Type: Grant
    Filed: January 27, 2006
    Date of Patent: December 22, 2009
    Assignees: Janssen Alzheimer Immunotherapy, Wyeth
    Inventors: Nicholas W. Warne, Donna Luisi, Angela Kantor
  • Canine vaccine for protection against ehrlichiosis
    Patent number: 7635481
    Abstract: The present invention provides a safe and effective vaccine composition which comprises: an effective immunizing amount of an inactivated Ehrlichia canis bacterin; a pharmacologically acceptable carrier; and an immunogenically stimulating amount of an adjuvant system consisting essentially of an antibody response inducing agent and a cell-mediated immunity response inducing agent. The present invention also provides a method for the prevention or amelioration of canine ehrlichiosis in dogs.
    Type: Grant
    Filed: April 20, 2006
    Date of Patent: December 22, 2009
    Assignee: Wyeth
    Inventors: Liangbiao (George) Hu, Thomas J. Hess, Yu-Wei Chiang, Hsien-Jue (Steve) Chu
  • Antineoplastic Combinations Containing HKI-272 and Vinorelbine
    Publication number: 20090312360
    Abstract: A combination of HKI-272 compound and a vinorelbine compound in the treatment of a neoplasm is provided. Regimens, kits, and methods for treatment of neoplasm, including breast cancer including metastatic breast cancer, and lung cancer, using this combination, optionally in combination with other anti-neoplastic agents, or immune modulators are also described.
    Type: Application
    Filed: June 17, 2009
    Publication date: December 17, 2009
    Applicant: Wyeth
    Inventor: Charles Michael Zacharchuk
  • Processes for the convergent synthesis of calicheamicin derivatives
    Publication number: 20090312530
    Abstract: This invention describes processes for the convergent synthesis of calicheamicin derivatives, and similar analogs using bifunctional and trifunctional linker intermediates.
    Type: Application
    Filed: August 17, 2009
    Publication date: December 17, 2009
    Applicant: Wyeth
    Inventors: Justin Keith Moran, Jianxin Gu
  • Methods and Compositions for Selective Inhibition of Ligand Binding to the Lectin-Like Receptor for Oxidized Low Density Lipoprotein (LOX-1)
    Publication number: 20090311271
    Abstract: The present invention provides methods of selectively inhibiting the binding of one ligand for LOX-1, but not one other ligand for LOX-1. Moreover, the invention relates to the identification of binding partners that act in a selective manner to inhibit the binding of one ligand to LOX-1, but not one other ligand for LOX-1, and methods of identifying such binding partners. Pharmaceutical compositions comprising the binding partners for LOX-1, in particular, anti-LOX-1 antibodies or fragments thereof, are also provided in the present invention.
    Type: Application
    Filed: May 28, 2009
    Publication date: December 17, 2009
    Applicant: Wyeth
    Inventors: Douglas Carl Harnish, Songwen Zhang, Macy Xiaohang Jin
  • 3-SUBSTITUTED-1H-INDOLE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES
    Publication number: 20090311217
    Abstract: The invention relates to 3-substituted-1H-indole compounds of the Formula I: or a pharmaceutically acceptable salt thereof, wherein the constituent variables are as defined herein, compositions comprising the compounds, and methods for making and using the compounds.
    Type: Application
    Filed: May 28, 2009
    Publication date: December 17, 2009
    Applicant: Wyeth
    Inventors: Matthew Gregory Bursavich, Nan Zhang, Semiramis Ayral-Kaloustian, James Thomas Anderson, Thai Hiep Nguyen, Sabrina Lombardi, David Malwitz, Natasja Brooijmans, Derek Cecil Cole, Adam Matthew Gilbert, Pawel Wojciech Nowak, Kaapjoo Park, Sasmita Das, Hwei-Ru Tsou, Aranapakam Mudumbai Venkatesan, Mercy Adufa Otteng, Gary Harold Birnberg, Gloria Jean MacEwan
  • FLUORESCENCE-BASED ASSAY FOR MONOACYLGLYCEROL LIPASE COMPATIBLE WITH INHIBITOR SCREENING
    Publication number: 20090311723
    Abstract: The present invention provides reagents, kits and methods for assaying monoglycerol lipase activity and for identifying compounds that modulate monoglycerol lipase (“MGL”) activity. A simple, sensitive fluorescence assay, which is amenable to high throughput screening, is described. In one embodiment, 7-Hydroxycoumarinyl-arachidonate (7-HCA) is used as a fluorogenic substrate for MGL, which catalyzes the hydrolysis of 7-HCA to generate arachidonic acid and the highly fluorescent 7-hydroxycoumarin (7-HC). Release of 7-HC is monitored continuously using a fluorometer. MGL protein catalyzed the hydrolysis of 7-HCA with an apparent KM of 9.8 mM and Vmax of 1.7 mmoles min?1 mg protein?1.
    Type: Application
    Filed: November 21, 2008
    Publication date: December 17, 2009
    Applicant: WYETH
    Inventors: Pranab Kumar Chanda, Yuren Wang
  • 11-beta HSD1 inhibitors
    Patent number: 7632838
    Abstract: This invention relates to inhibiting 11?HSD1.
    Type: Grant
    Filed: February 7, 2007
    Date of Patent: December 15, 2009
    Assignee: Wyeth
    Inventors: Jason Shaoyun Xiang, Eddine Saiah, Steve Y. Tam, John C. Mckew, Lihren Chen, Manus Ipek, Huan-Qiu Li, Jianchang Li, Wei Li, Tarek Suhayl Mansour, Vipin Suri, Yuchuan Wu, Zhao-Kui Wan, Jinbo Lee, Eva Binnun, Douglas P. Wilson
  • Phenyl quinolines and their use as estrogenic agents
    Patent number: 7632845
    Abstract: This invention provides estrogen receptor modulators of formula I, having the structure wherein, R1, R2, R3, R4, R5, and R6 are as defined in the specification, or a N-oxide thereof or a pharmaceutically acceptable salt thereof or a prodrug thereof.
    Type: Grant
    Filed: May 31, 2006
    Date of Patent: December 15, 2009
    Assignee: Wyeth
    Inventors: An Thien Vu, Stephen Todd Cohn, Richard Eric Mewshaw
  • TANAPROGET DERIVATIVES, METABOLITES, AND USES THEREOF
    Publication number: 20090306000
    Abstract: A method of generating synthetic metabolites of tanaproget derivatives thereof is provided. These compounds and methods of using these derivatives for detecting tanaproget metabolites in samples are provided.
    Type: Application
    Filed: June 26, 2009
    Publication date: December 10, 2009
    Applicant: Wyeth
    Inventors: Li Shen, Kelly Keating, Oliver McConnell, William DeMaio, Appavu Chandrasekaran
  • TRIAZINE COMPOUNDS AS PI3 KINASE AND MTOR INHIBITORS
    Publication number: 20090304692
    Abstract: Compounds of formula I wherein: R1 is and R2, R4, and R6-9 are defined herein, and pharmaceutically acceptable salts and esters thereof. These compounds inhibit PI3 kinase and mTOR, and may be used to treat diseases mediated by PI3 kinase and mTOR, such as a variety of cancers. Methods for making and using the compounds of this invention are disclosed. Various compositions containing the compounds of this invention are also disclosed.
    Type: Application
    Filed: May 22, 2009
    Publication date: December 10, 2009
    Applicant: Wyeth
    Inventors: Aranapakam Mudumbai Venkatesan, Zecheng Chen, Christoph Martin Dehnhardt, Osvaldo dos Santos, Efren Guillermo Delos Santos, Arie Zask, Jeroen Cunera Verheijen, Joshua Aaron Kaplan, David James Richard, Semiramis Ayral-Kaloustian, Tarek Suhayl Mansour, Ariamala Gopalsamy, Kevin Joseph Curran, Mengxiao Shi
  • CYANOPYRROLE CONTAINING CYCLIC CARBAMATE AND THIOCARBAMATE BIARYLS AND METHODS FOR PREPARING THE SAME
    Publication number: 20090306371
    Abstract: Methods for preparing cyclic carbamates and thiocarbamates containing cyanopyrrole moieties and of the formula are provided. Z are the same or different and are H, optionally substituted C1 to C6 alkyl, or CORA; RA is H, optionally substituted C1 to C6 alkyl, optionally substituted C1 to C6 alkoxy, or optionally substituted C1 to C6 aminoalkyl; Q are the same or different and are H, OH, NH2, CN, halogen, optionally substituted C1 to C6 alkyl, optionally substituted C2 to C6 alkenyl, optionally substituted C1 to C6 alkynyl, optionally substituted C1 to C6 alkoxy, optionally substituted C1 to C6 aminoalkyl, or CORB; and RB is H, optionally substituted C1 to C6 alkyl, optionally substituted C1 to C6 alkoxy, or optionally substituted C1 to C6 aminoalkyl.
    Type: Application
    Filed: July 24, 2009
    Publication date: December 10, 2009
    Applicant: Wyeth
    Inventor: Bogdan Kazimierz Wilk
  • Therapeutic compositions and methods
    Publication number: 20090304590
    Abstract: The present application provides novel binding proteins, including human binding proteins that specifically bind to the human ErbB2.
    Type: Application
    Filed: October 27, 2008
    Publication date: December 10, 2009
    Applicants: Wyeth, Trubion Pharmaceuticals, Inc.
    Inventors: Davinder Singh Gill, Laird Bloom, Maximillian T. Follettie, Fionnuala McAleese, Sreekumar Kodangattil, John Francis DiJoseph, Nitin K. Damle, Peter R. Baum, Peter A. Thompson, John C. Kumer, Alan F. Wahl, Paul A. Algate, Sateesh Kumar Natarajan
  • Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1)
    Patent number: 7629377
    Abstract: This invention provides PAI-1 inhibiting compounds of Formula I: wherein: R1, R2, R3, and R4 are each H, alkyl, alkanoyl, halo, OH, aryl optionally substituted with R8, perfluoroalkyl, alkoxy, amino, alkylamino, dialkylamino, perfluoroalkoxy; R5 is H, alkyl, perfluoroalkyl, aryl optionally substituted with R5, alkanoyl, aroyl optionally substituted with R8; R6 is H, alkyl, alkylaryl, benzyl optionally substituted with R8, alkanoyl, aroyl optionally substituted with R8; R7 is H, alkyl, alkylaryl, aryl optionally substituted with R8; n is 0-6; A is COOH, or an acid mimic such as tetraazole, SO3H, PO3H2, tetronic acid, etc.; R8 is H, alkyl, cycloalkyl, alkanoyl, halo, OH, perfluoroalkyl, alkoxy, amino, alkylamino, dialkylamino, perfluoroalkoxy; or a pharmaceutically acceptable salt thereof; as well as pharmaceutical compositions and methods of treatment using these compounds.
    Type: Grant
    Filed: February 5, 2008
    Date of Patent: December 8, 2009
    Assignee: Wyeth
    Inventors: David LeRoy Crandall, Scott Christian Mayer, Eric Gould Gundersen, Hassan Mahmoud Elokdah
  • ANTINEOPLASTIC COMBINATIONS WITH mTOR INHIBITOR, TRASTUZUMAB, AND/OR HKI-272
    Publication number: 20090297519
    Abstract: A combination of temsirolimus and trastuzumab in the treatment of cancer is provided. A combination of temsirolimus and HKI-272 is provided. A combination of a trastuzumab and a HKI-272 is also provided. Regimens and kits for treatment of metastatic breast cancer, containing trastuzumab, temsirolimus and/or HKI-272, optionally in combination with other anti-neoplastic agents, or immune modulators are described.
    Type: Application
    Filed: August 12, 2009
    Publication date: December 3, 2009
    Applicant: Wyeth
    Inventors: Laurence Moore, Charles Zacharchuk, Sridhar K. Rabindran
  • METHODS OF TREATMENT UTILIZING BINDING PROTEINS OF THE INTERLEUKIN-21 RECEPTOR
    Publication number: 20090298081
    Abstract: The present invention provides binding proteins and antigen-binding fragments thereof, including human antibodies, that specifically bind to the human interleukin-21 receptor (IL-21R), and methods of using them. The binding proteins can act as, e.g., antagonists of IL-21R activity, thereby modulating immune responses in general, and those mediated by IL-21R in particular. The disclosed compositions and methods may be used, e.g., in diagnosing, treating, and/or preventing IL-21R-associated disorders, e.g., inflammatory disorders, autoimmune diseases, allergies, transplant rejection, and other immune system disorders.
    Type: Application
    Filed: May 26, 2009
    Publication date: December 3, 2009
    Applicant: WYETH
    Inventors: Laird BLOOM, Davinder GILL, Yulia VUGMEYSTER, Deborah A. YOUNG, Margot O'TOOLE, Heath M. GUAY, Karissa K. ADKINS, Amy Arlene WEAVER, Sadhana JAIN, Maya ARAI
  • INTERLEUKIN-21 RECEPTOR BINDING PROTEINS
    Publication number: 20090298167
    Abstract: The present invention provides binding proteins and antigen-binding fragments thereof that specifically bind to the human interleukin-21 receptor (IL-21R). The binding proteins can act as, e.g., antagonists of IL-21R activity, thereby modulating immune responses in general, and those mediated by IL-21R in particular. The disclosed compositions and methods may be used, e.g., in diagnosing and/or treating IL-21R-associated disorders, e.g., inflammatory disorders, autoimmune diseases, allergies, transplant rejection, cancer, and other immune system disorders.
    Type: Application
    Filed: May 26, 2009
    Publication date: December 3, 2009
    Applicants: WYETH, MEDIMMUNE LIMITED
    Inventors: Laird BLOOM, Davinder GILL, Yulia VUGMEYSTER, Deborah A. YOUNG, David LOWE, Viia VALGE-ARCHER
  • 3-SUBSTITUTED-1H-PYRROLO[2,3-B]PYRIDINE AND 3-SUBSTITUTED-1H-PYRROLO[3,2-B]PYRIDINE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES
    Publication number: 20090298820
    Abstract: The invention relates to 3-substituted-1H-pyrrolo[2,3-b]pyridine, and 3-substituted-1H-pyrrolo[3,2-b]pyridine compounds of the Formula 1: or a pharmaceutically acceptable salt thereof, wherein the constituent variables are as defined herein, compositions comprising the compounds, and methods for making and using the compounds.
    Type: Application
    Filed: May 28, 2009
    Publication date: December 3, 2009
    Applicant: Wyeth
    Inventors: Hwei-Ru Tsou, Gary Harold Birnberg, Gloria Jean MacEwan, Semiramis Ayral-Kaloustian, Matthew Gregory Bursavich, Sabrina Lombardi, Nan Zhang, Adam Matthew Gilbert, George Theordore Grosu, Natasja Brooijmans, Thai Hiep Nguyen